Background:

Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted[1].

Repaglinide (AG-EE 623ZW) is very rapidly absorbed (tmax less than 1 hour) with a t1/2 of less than one hour. Furthermore, Repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) is effective (P<0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes.

参考文献:
[1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore). 2018 Sep;97(38):e12476.